COVID-19 Impact: Cancer Deaths Rose, Survival Fell

The COVID-19 pandemic’s shadow extends far beyond infection rates and economic disruption, now demonstrably impacting cancer survival rates with a chilling effect. A new study published February 5, 2026, in JAMA Oncology reveals that patients diagnosed with cancer in the U.S. during the first two years of the pandemic experienced significantly lower one-year survival rates, resulting in an estimated 17,390 excess deaths. This isn’t simply a matter of delayed care; it’s a stark indicator of systemic vulnerabilities within our healthcare infrastructure and a harbinger of potential long-term consequences for cancer outcomes.

The initial disruptions to cancer care – missed screenings, delayed diagnoses, and interrupted treatment – were flagged as major concerns early in the pandemic. However, quantifying the impact on survival rates required the availability of comprehensive national cancer registry data. This study, leveraging data from the SEER-21 registries (covering roughly 42% of the U.S. population), provides that crucial insight. The findings validate earlier observations from former National Cancer Institute (NCI) Director Norman Sharpless, who warned in 2021 that a nearly 50% drop in cancer diagnoses early in the pandemic wasn’t a sign of fewer cases, but rather a dangerous backlog created by delayed care. He correctly predicted that this would translate to more advanced-stage diagnoses and, ultimately, increased mortality.

The study’s focus on cancer-specific survival – isolating deaths directly attributable to cancer – strengthens its conclusions by minimizing the influence of COVID-19 related deaths that might otherwise skew the data. The fact that declines were observed across most demographic groups and cancer types underscores the widespread nature of the problem. The particularly stark impact on older adults and those from underserved communities is especially concerning, reflecting existing health disparities exacerbated by pandemic-related barriers to care, including limited access to telehealth and routine medical services.

The Forward Look

While this study provides a sobering assessment of the pandemic’s immediate impact, the long-term implications are potentially even more significant. The backlog of delayed diagnoses hasn’t disappeared. We can anticipate a continued surge in late-stage cancer diagnoses in the coming years, placing further strain on an already burdened healthcare system. The focus now must shift to proactive measures. Expect increased investment in mobile screening units targeting underserved communities, and a renewed emphasis on telehealth infrastructure to improve access to care. Furthermore, the study highlights the critical need for greater health system resilience – the ability to maintain essential services during future public health emergencies.

Looking ahead, researchers will need to investigate the long-term effects of COVID-19 infection on cancer development and progression. The authors of this study rightly call for further research to clarify these effects and to address the gaps in our understanding. Finally, the findings should serve as a catalyst for policy changes aimed at strengthening cancer prevention and early detection programs, ensuring that the lessons learned from this pandemic are not forgotten. The 17,390 excess deaths are not just a statistic; they represent a call to action to build a more robust and equitable cancer care system for the future.